Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine the changes in macular function during anti-VEGF treatment for neovascular age-related macular degeneration.
Macular function will be investigated using visual acuity, contrast sensitivity, mfERG and microperimetry.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group A | Patients investigated with mfERG and MP-1 | ||
| Group B | Patients investigated by Laser Doppler Flowmetry |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| mfERG central ring amplitude density | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Mean retinal sensitivity (dB) in three concentric rings (4°, 8° & 12°) | 12 months | |
| Choroidal blood flow (ChBFlow) at fovea and at optic nerve head | 12 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
AMD clinic
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Simon P Harding, FRCOphth, MD | Contact | +44 0151 706 | 3966 | S.P.Harding@liverpool.ac.uk |
| Claudio S Campa, MD, PhD | Contact | +44 0151 706 | 3939 | Claudio.Campa@rlbuht.nhs.uk |
| Name | Affiliation | Role |
|---|---|---|
| Simon P HARDING, FRCOphth, MD | University of Liverpool | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinical Eye Research Centre | Recruiting | Liverpool | L7 8XP | United Kingdom |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 21357390 | Derived | Campa C, Hagan R, Sahni JN, Brown MC, Beare NA, Heimann H, Harding SP. Early multifocal electroretinogram findings during intravitreal ranibizumab treatment for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011 Jun 1;52(6):3446-51. doi: 10.1167/iovs.10-6588. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008268 | Macular Degeneration |
| ID | Term |
|---|---|
| D012162 | Retinal Degeneration |
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided